BofA Upgrades Bristol-Myers Squibb (BMY) Stock to Buy from Neutral

Group 1 - Bristol-Myers Squibb Company (NYSE:BMY) is considered one of the best stocks to invest in for the next three years, with a recent upgrade from BofA to "Buy" from "Neutral" and a price target increase from $52 to $61 [1] - BofA anticipates that 4-6 programs in the company's R&D pipeline will deliver key de-risking catalysts in the near term, viewing the current stock weakness as a buying opportunity [1][2] - The firm projects a return to growth for Bristol-Myers Squibb by 2029 and beyond, applying a 10x P/E multiple to the FY 2027 estimated EPS, up from the previous 8x multiple for 2026 estimates [2] Group 2 - On December 11, Bristol-Myers Squibb announced that the US FDA accepted and granted priority review for the supplemental Biologics License Application (sBLA) for Opdivo® in combination with AVD for treating previously untreated Stage III or IV classical Hodgkin Lymphoma [3]